The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of REGN421 (R)/SAR153192, a fully-human delta-like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors.
Antonio Jimeno
Research Funding - Regeneron
Patricia LoRusso
Research Funding - Regeneron
Robert Matthew Strother
Research Funding - Regeneron
Jennifer Robinson Diamond
Research Funding - Regeneron
Leah Plato
Research Funding - Regeneron
Anne Younger
Research Funding - Regeneron
Wells A. Messersmith
Research Funding - Regeneron (B)
Muaiad Kittaneh
Research Funding - Regeneron
Doug Sawyer
Consultant or Advisory Role - Regeneron (U)
Lieve Adriaens
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Liming Liu
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Richard J. Kao
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
A Thomas DiCioccio
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Carrie M. Brownstein
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Israel Lowy
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Pamela Trail
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
E. Gabriela Chiorean
Research Funding - Regeneron